Dimethylfumarat in der therapie der schubförmigen MS: Verträglichkeit und management von nebenwirkungen

Translated title of the contribution: Dimethylfumarate as therapy for relapsing-remitting multiple sclerosis

K. Baum, H. J. Boldt, A. Chan, L. Harms, H. P. Hartung, B. C. Kieseier, T. Korn, M. Mäurer, U. Meier, H. Schreiber, B. Tackenberg, H. Wiendl, T. Ziemssen, R. Gold

Research output: Contribution to journalArticlepeer-review


Until recently, disease modifying platform therapies for relapsing-remitting multiple sclerosis (MS) were limited to injectable drugs. With the introduced dimethylfumarate (DMF, Tecfidera®) an oral first-line MS therapy became available. In clinical phase III studies, DMF showed good efficacy and safety. Oral application may facilitate the integration of treatment in the everyday routine of patients, thereby potentially increasing treatment adherence. DMF was well tolerated in the clinical trials. Treatment discontinuations due to adverse events were infrequent. Side-effects, for instance gastrointestinal symptoms and flush, remained mostly mild to moderate; their incidence was highest in the first 1 to 3 months after treatment initiation and decreased thereafter. Reduced initial dosage, intake with food, usual symptomatic medications, acetylsalicylic acid as premedication (temporary), and optional temporary dose reduction may reduce these symptoms. These measures may help affected patients to bridge the initial treatment phase, thus enabling consistent long term therapy with this highly promising MS medication.

Translated title of the contributionDimethylfumarate as therapy for relapsing-remitting multiple sclerosis
Original languageGerman
Pages (from-to)175-179
Number of pages5
Issue number3
StatePublished - 2014
Externally publishedYes


Dive into the research topics of 'Dimethylfumarate as therapy for relapsing-remitting multiple sclerosis: Verträglichkeit und management von nebenwirkungen'. Together they form a unique fingerprint.

Cite this